Non-Small Cell Lung Cancer - Pipeline Review, H1 2020
Non-Small Cell Lung Cancer - Pipeline Review, H1 2020
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2020, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 21, 65, 327, 273, 23, 249, 46 and 12 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 16, 22, 51 and 4 molecules, respectively.
Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Non-Small Cell Lung Cancer - Overview
Non-Small Cell Lung Cancer - Therapeutics Development
Non-Small Cell Lung Cancer - Therapeutics Assessment
Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development
Non-Small Cell Lung Cancer - Drug Profiles
Non-Small Cell Lung Cancer - Dormant Projects
Non-Small Cell Lung Cancer - Discontinued Products
Non-Small Cell Lung Cancer - Product Development Milestones
Appendix
Tables and Figures
List of Tables
Number of Products under Development for Non-Small Cell Lung Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Number of Products by Stage and Molecule Type, H1 2020 (Contd..1), H1 2020
Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by 4D Pharma Plc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H1 2020
Non-Small Cell Lung Cancer - Pipeline by A&G Pharmaceutical Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2020
Non-Small Cell Lung Cancer - Pipeline by ABM Therapeutics Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by AC Bioscience SA, H1 2020
Non-Small Cell Lung Cancer - Pipeline by ACEA Therapeutics Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Achilles Therapeutics Ltd, H1 2020
Non-Small Cell Lung Cancer - Pipeline by AcuityBio Corp, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by ADC Therapeutics SA, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Aduro BioTech Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Advanced BioDesign, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Advaxis Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Adze Biotechnology Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Agenus Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Agilvax Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Agios Pharmaceuticals Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by AIM ImmunoTech Inc, H1 2020
Non-Small Cell Lung Cancer - Pipeline by Akeso Inc, H1 2020
Companies Mentioned
3SBio Inc
4D Pharma Plc
4SC AG
A&G Pharmaceutical Inc
A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
Ability Pharmaceuticals SL
ABM Therapeutics Inc
AC Bioscience SA
ACEA Therapeutics Inc
Achilles Therapeutics Ltd
AcuityBio Corp
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Aduro BioTech Inc
Advanced BioDesign
Advaxis Inc
Advenchen Laboratories LLC
Adze Biotechnology Inc
Agenus Inc
Agilvax Inc
Agios Pharmaceuticals Inc
AIM ImmunoTech Inc
Akeso Inc
Alethia Biotherapeutics Inc
Alkermes Plc
Alligator Bioscience AB
Allist Shanghai Pharmaceutical Technology Co Ltd
Almac Discovery Ltd
Alpha Biopharma
Alphamab Oncology
Altum Pharmaceuticals Inc
ALX Oncology Inc
amcure GmbH
Amgen Inc
AmMax Bio Inc
Amphivena Therapeutics Inc
Andarix Pharmaceuticals Inc
Anew Oncology Inc
AnHeart Therapeutics Inc
Anhui Anke Biotechnology (Group) Co Ltd
Antapodia Therapeutics Inc
Antengene Corp
AP Biosciences Inc
Apexigen Inc
Apollomics Inc
Apotex Inc
Aprea Therapeutics AB
Aptarion biotech AG
Araxes Pharma LLC
Arch Oncology Inc
Arcus Biosciences Inc
Aro Biotherapeutics Co
Arvinas Inc
Asana BioSciences LLC
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Astellas Pharma Inc
AstraZeneca Plc
Atreca Inc
AUM Biosciences Pte Ltd
Aurigene Discovery Technologies Ltd
Aurobindo Pharma Ltd
Axelar AB
Basilea Pharmaceutica Ltd
Batu Biologics Inc
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing Biostar Technologies Ltd
Beijing Eastern Biotech Co Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Beijing Kawin Technology Share-Holding Co Ltd
Beijing Luzhu Biotechnology Co Ltd
Beijing Mabworks Biotech Co Ltd
Beijing Pearl Biotechnology LLC
BerGenBio ASA
Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
BeyondSpring Inc
Bicycle Therapeutics Plc
Binjiang Pharma, Inc.
Bio-Path Holdings Inc
Bio-Thera Solutions Ltd
BioAtla LLC
Biocad
BIOCND Inc
Biocon Ltd
Biohaven Pharmaceutical Holding Company Ltd
BioIntegrator Ltd
BioInvent International AB
BioLineRx Ltd
BioMarck Pharmaceuticals Ltd
BioMed Valley Discoveries Inc
BioNTech SE
Biosion Inc
Biothera Pharmaceutical Inc
Bioven Group
BioXpress Therapeutics SA
BJ Bioscience Inc
Blueprint Medicines Corp
Boehringer Ingelheim International GmbH
Boston Biomedical Inc
Boston Pharmaceuticals Inc
BriaCell Therapeutics Corp
Bridge Biotherapeutics Inc
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
Calithera Biosciences Inc
CanBas Co Ltd
Candel Therapeutics
Cantargia AB
CARsgen Therapeutics Ltd
CAS-Lamvac Biotech Co Ltd
Cascade Prodrug Inc
CDR-Life Inc
Cellatoz Therapeutics Inc
Celldex Therapeutics Inc
Cellestia Biotech AG
Cellmid Ltd
Celltrion Inc
Cellular Biomedicine Group Inc
Cellworks Group Inc
Celon Pharma SA
Centaurus Biopharma Co Ltd
Centurion BioPharma Corp
Centus Biotherapeutics Ltd
Checkmate Pharmaceuticals Inc
Checkpoint Therapeutics Inc
Chi Cheung (Shanghai) Biomedical Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chineo Med Beijing Co Ltd
Chiome Bioscience Inc
Chipscreen Biosciences Ltd
Chong Kun Dang Pharmaceutical Corp
Chugai Pharmaceutical Co Ltd
Cipla BioTec Pvt Ltd
Cleveland BioLabs Inc
Cloaked Therapeutics LLC
Clovis Oncology Inc
Co-D Therapeutics Inc
Compugen Ltd
Constellation Pharmaceuticals Inc
Convert Pharmaceuticals SA
Corcept Therapeutics Inc
Cortice Biosciences Inc
Corvus Pharmaceuticals Inc
Cotinga Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Cumberland Pharmaceuticals Inc
Cureport Inc
Cyclica Inc
Cytocom Inc
Cytocraft Bio-Tech Development Co Ltd
CytomX Therapeutics Inc
DAE HWA Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Debiopharm International SA
Deciphera Pharmaceuticals Inc
DEKK-TEC Inc
DelMar Pharmaceuticals Inc
Delta-Fly Pharma Inc
DiNonA Inc
Dizal (Jiangsu) Pharmaceutical Co Ltd
Domainex Ltd
Dr. Reddy's Laboratories Ltd
Dragonfly Therapeutics Inc
Druggability Technologies Holdings Ltd
Dynavax Technologies Corp
eFFECTOR Therapeutics Inc
EirGenix Inc
Eisai Co Ltd
Eleison Pharmaceuticals LLC
Eli Lilly and Co
Elicio Therapeutics
EnGeneIC Ltd
Enochian Biosciences Inc
EntreChem SL
Enzene Biosciences Ltd
EpicentRx Inc
Epidestiny Inc
EpimAb Biotherapeutics Inc
Epizyme Inc
Epygen Biotech Pvt Ltd
Ergon Pharmaceuticals LLC
Esanex Inc
Essential Biotechnology LLC
Eudendron Srl
Eutilex Co Ltd
Evaxion Biotech ApS
Evelo Biosciences Inc
Evestra Inc
Evotec SE
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
FibroStatin SL
Five Prime Therapeutics Inc
Fochon Pharma Inc
Fochon Pharmaceutical Ltd
Forbius
Formosa Pharmaceuticals Inc
Fresenius SE & Co KGaA
Fujifilm Holdings Corp
G&E Corp
G1 Therapeutics Inc
Galectin Therapeutics Inc
Galera Therapeutics Inc
GC Pharma
GEEN Biotechnology Inc
GEMoaB Monoclonals GmbH
Gene Techno Science Co Ltd
GeneFrontier Corp
Genelux Corp
Genentech Inc
Geneos Therapeutics Inc
Genexine Inc
GenFleet Therapeutics (Shanghai) Inc
Genmab AS
Genocea Biosciences Inc
Genome & Co
Genor BioPharma Co Ltd
Genosco Inc
Genprex Inc
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets